MRK vs REGN
By Alex · Tickerpine
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | REGN |
|---|---|---|
| Price | $145.27 | $805.02 |
| Market cap | $358.41B | $82.88B |
| P/E ratio | 117.2 | 19.9 |
| ROE | 6.96% | 14.04% |
| Profit margin | 4.77% | 27.87% |
| Revenue growth | 5.10% | 16.70% |
| Dividend yield | 2.34% | 0.47% |
| Beta | 0.22 | 0.15 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs REGN in plain English
- MRK is the bigger company — about 4.3× the market cap of REGN.
- REGN is cheaper on earnings (P/E 19.9 vs 117.2).
- REGN earns a higher return on equity (14% vs 7%).
- REGN is growing revenue faster (17% vs 5%).
- MRK has the higher dividend yield (2.34% vs 0.47%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.